Dalcetrapib for COVID-19
NCT04676867 · May 2021
Outcome
Improvement
Relative Risk · 95% CI
00.511.52+
← Dalcetrapib
reduces riskDalcetrapib
increases risk →
reduces riskDalcetrapib
increases risk →
Trial underpowered to detect differences